Calliditas Therapeutics IPO Presentation Deck
COVID-19 business impact
Phase 3 study continues to be on plan
Over 146 clinical sites activated and recruiting across 19 countries
Significant part of Q1 focused on analyzing potential impact of the virus across different geographic regions
and putting mitigating solutions in place to ensure patient safety and trial integrity
Limited impact to date on NeflgArd:
Part A fully recruited in December 2019
Oral medication
#
■
·
■
Limited interaction with healthcare system
Successful implementation of strategy encompassing CRO, national coordinators and site staff to minimize
potential impact
Helpful guidance received from regulatory bodies.
Part B of Phase 3 NefigArd trial: full recruitment still anticipated to be competed before end of 2020 based on
recruited number of patients to date and recent increase in activities in China
calliditas
June 2020
18View entire presentation